BACKGROUND: Survival studies have consistently shown significantly greater mortality rates in underweight and normal-weight patients with chronic obstructive pulmonary disease (COPD) than in overweight and obese COPD patients. OBJECTIVE: To compare the contributions of low fat-free mass and low fat mass to mortality, we assessed the association between body composition and mortality in COPD. DESIGN: We studied 412 patients with moderate-to-severe COPD [Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) stages II-IV, forced expiratory volume in 1 s of 36 +/- 14% of predicted (range: 19-70%). Body composition was assessed by using single-frequency bioelectrical impedance. Body mass index, fat-free mass index, fat mass index, and skeletal muscle index were calculated and related to recently developed reference values. COPD patients were stratified into defined categories of tissue-depletion pattern. Overall mortality was assessed at the end of follow-up. RESULTS: Semistarvation and muscle atrophy were equally distributed among disease stages, but the highest prevalence of cachexia was seen in GOLD stage IV. Forty-six percent of the patients (n = 189) died during a maximum follow-up of 5 y. Cox regression models, with and without adjustment for disease severity, showed that fat-free mass index (relative risk: 0.90; 95% CI: 0.84, 0.96; P = 0.003) was an independent predictor of survival, but fat mass index was not. Kaplan-Meier and Cox regression plots for cachexia and muscle atrophy did not differ significantly. CONCLUSIONS: Fat-free mass is an independent predictor of mortality irrespective of fat mass. This study supports the inclusion of body-composition assessment as a systemic marker of disease severity in COPD staging.
BACKGROUND: Survival studies have consistently shown significantly greater mortality rates in underweight and normal-weight patients with chronic obstructive pulmonary disease (COPD) than in overweight and obese COPDpatients. OBJECTIVE: To compare the contributions of low fat-free mass and low fat mass to mortality, we assessed the association between body composition and mortality in COPD. DESIGN: We studied 412 patients with moderate-to-severe COPD [Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) stages II-IV, forced expiratory volume in 1 s of 36 +/- 14% of predicted (range: 19-70%). Body composition was assessed by using single-frequency bioelectrical impedance. Body mass index, fat-free mass index, fat mass index, and skeletal muscle index were calculated and related to recently developed reference values. COPDpatients were stratified into defined categories of tissue-depletion pattern. Overall mortality was assessed at the end of follow-up. RESULTS: Semistarvation and muscle atrophy were equally distributed among disease stages, but the highest prevalence of cachexia was seen in GOLD stage IV. Forty-six percent of the patients (n = 189) died during a maximum follow-up of 5 y. Cox regression models, with and without adjustment for disease severity, showed that fat-free mass index (relative risk: 0.90; 95% CI: 0.84, 0.96; P = 0.003) was an independent predictor of survival, but fat mass index was not. Kaplan-Meier and Cox regression plots for cachexia and muscle atrophy did not differ significantly. CONCLUSIONS: Fat-free mass is an independent predictor of mortality irrespective of fat mass. This study supports the inclusion of body-composition assessment as a systemic marker of disease severity in COPD staging.
Authors: Emily S Wan; Michael H Cho; Nadia Boutaoui; Barbara J Klanderman; Jody S Sylvia; John P Ziniti; Sungho Won; Christoph Lange; Sreekumar G Pillai; Wayne H Anderson; Xiangyang Kong; David A Lomas; Per S Bakke; Amund Gulsvik; Elizabeth A Regan; James R Murphy; Barry J Make; James D Crapo; Emiel F Wouters; Bartolome R Celli; Edwin K Silverman; Dawn L DeMeo Journal: Am J Respir Cell Mol Biol Date: 2010-10-29 Impact factor: 6.914
Authors: A Travassos; A Rodrigues; K C Furlanetto; L Donária; G W Bisca; A G Nellessen; F Pitta; N A Hernandes Journal: Eur J Clin Nutr Date: 2017-07-19 Impact factor: 4.016
Authors: Grace Trompeter; Matthew R Grigsby; Catherine H Miele; Robert A Wise; Robert H Gilman; J Jaime Miranda; Antonio Bernabe-Ortiz; William Checkley Journal: Lung Date: 2018-03-20 Impact factor: 2.584
Authors: J Nordén; A M Grönberg; I Bosaeus; H Bertéus Forslund; L Hulthén; E Rothenberg; J Karlsson; O Wallengren; F Slinde Journal: Eur J Clin Nutr Date: 2014-05-07 Impact factor: 4.016